Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Uridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.88 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.88 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.88 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.88 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL5566644 | 1.00 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4081077 | 0.96 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1495318 | 0.95 | SLC28A1 (0.83) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL6926760 | 0.94 | SLC28A1 (0.85) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056634 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2912983 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4455604 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL20987631 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2056530 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL9945547 | 0.94 | SLC28A1 (1.00) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284341-B1 | URIDINE TRIACETATE AMORPHOUS FORMULATION | PHARMA CINQ LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4561539-A1 | URIDINE TRIACETATE AMORPHOUS FORMULATION AND USES THEREOF | Pharma Cinq, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| CN-119816299-A | Amorphous formulations of uridine triacetate and uses thereof | 制药五有限责任公司 | 2025-04-11 | — | — | CN | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119546336-A | Allo-low immunity bionic nano vesicle for treating cancer | T·马尔科姆 | 2025-02-28 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2018102506-A1 | TYROSINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM | TYME, INC. (US) | 2018-06-07 | — | — | WO | claimed |
| CN-107875165-A | It is a kind of treat tumour radiotherapy caused by bone marrow suppression Percutaneously administrable preparation | 宋在明 | 2018-04-06 | — | — | CN | claimed |
| CN-107753490-A | It is a kind of treat tumor radiotherapy caused by oral mucositis Percutaneously administrable preparation | 宋在明 | 2018-03-06 | — | — | CN | claimed |
| CN-107595873-A | It is a kind of treat tumor radiotherapy caused by radiodermatitis Percutaneously administrable preparation | 宋在明 | 2018-01-19 | — | — | CN | claimed |
| US-20170209476-A1 | Treatment of Glycosylation Deficiency Diseases | WELLSTAT THERAPEUTICS CORPORATION (US) | 2017-07-27 | — | — | US | claimed |
| EP-3182980-A1 | TREATMENT OF GLYCOSYLATION DEFICIENCY DISEASES | Wellstat Therapeutics Corporation (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2017070445-A1 | METHODS OF TREATMENT OF RHABDOMYOLYSIS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-04-27 | — | — | WO | claimed |
| US-20170115275-A1 | ENGINEERED SUBSTRATES FOR HIGH-THROUGHPUT GENERATION OF 3D MODELS OF TUMOR DORMANCY, RELAPSE AND MICROMETASTASES FOR PHENOTYPE SPECIFIC DRUG DISCOVERY AND DEVELOPMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-04-27 | — | — | US | claimed |
| US-20170080093-A1 | Tyrosine Derivatives And Compositions Comprising Them | TYME, INC. | 2017-03-23 | — | — | US | claimed |
| WO-2016028894-A1 | TREATMENT OF GLYCOSYLATION DEFICIENCY DISEASES | WELLSTAT THERAPEUTICS CORPORTION (US) | 2016-02-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170080093-A1 | Tyrosine Derivatives And Compositions Comprising Them | TYR, TH, ABL1 | SLC28A1 2089/4885SLC28A2 2489/4885SLC29A1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.